Normally a company
invests a great
deal of money
in research and development to get a
drug to market, then recoups that, and profits, by selling it.
«While a great
deal of money has been
invested in developing schizophrenia
drugs, a similar investment hasn't been made to develop biomarkers that could improve the reliability and consistency of test results,» said Daniel Javitt, MD, PhD, professor of psychiatry and Director of the Division of Experimental Therapeutics at CUMC, Director of schizophrenia research at the Nathan Kline Institute for Psychiatric Research, and Co-Principal Investigator of the study.